Clinical Trial

Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)

Name: Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) — clinical trial record (NCT07603557)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and autoimmune hemolytic anemia (AIHA).

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-05-18.

Trial Details

NCT Number	NCT07603557
Lead Sponsor	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Conditions	Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
Enrollment	52 participants
Start Date	2026-08-31
Primary Completion	2030-05-06 (estimated)
Study Completion	2030-05-06 (estimated)
Updated on ClinicalTrials.gov	2026-07-09